edotreotide has been researched along with lutetium in 15 studies
| Studies (edotreotide) | Trials (edotreotide) | Recent Studies (post-2010) (edotreotide) | Studies (lutetium) | Trials (lutetium) | Recent Studies (post-2010) (lutetium) |
|---|---|---|---|---|---|
| 206 | 34 | 86 | 1,192 | 44 | 844 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bijster, M; De Jong, M; Konijnenberg, MW; Krenning, EP | 1 |
| Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Valkema, R | 1 |
| Anderson, T; Atcher, R; Nayak, T; Norenberg, J | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F | 1 |
| Forrer, F; Maecke, HR; Mueller-Brand, J; Riedweg, I | 1 |
| Arveschoug, AK; Hjorthaug, K; Højgaard, L; Mortensen, J; Oturai, PS; Rehling, M | 1 |
| Bodei, L; Paganelli, G; Pepe, G | 1 |
| Applebaum, L; Barak, D; Eckstein, J; Fraenkel, M; Gross, DJ; Grozinsky-Glasberg, S; Müeller-Brand, J; Shimon, I; Walter, MA | 1 |
| Asti, M; Fioroni, F; Grassi, E; Iori, M; Piccagli, V; Sghedoni, R; Versari, A | 1 |
| Baum, RP; Kulkarni, HR; Müller, D; Prasad, V; Schuchardt, C; Zachert, C | 1 |
| Baum, RP; Kulkarni, HR; Schuchardt, C | 1 |
| Baum, RP; Kulkarni, HR; Prasad, V; Schuchardt, C | 1 |
| Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G | 1 |
| Baum, RP; Kulkarni, HR; Singh, A; Zhang, J | 1 |
| Cordes, M; Goetz, TI; Kuwert, T; Lang, EW; Maier, A; Prante, O; Ritt, P; Schmidkonz, C | 1 |
1 review(s) available for edotreotide and lutetium
| Article | Year |
|---|---|
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Topics: Antineoplastic Agents; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Somatostatin; Yttrium Radioisotopes | 2010 |
2 trial(s) available for edotreotide and lutetium
| Article | Year |
|---|---|
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
Topics: Adult; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Octreotide; Paraganglioma; Pheochromocytoma; Staining and Labeling; Yttrium Radioisotopes | 2008 |
12 other study(ies) available for edotreotide and lutetium
| Article | Year |
|---|---|
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Topics: Animals; Body Burden; Computer Simulation; Drug Evaluation, Preclinical; Femoral Neoplasms; Indium Radioisotopes; Lutetium; Metabolic Clearance Rate; Models, Biological; Octreotide; Organ Specificity; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Wistar; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Yttrium Radioisotopes | 2004 |
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Humans; Lutetium; Male; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Somatostatin; Survival Analysis; Treatment Outcome; Yttrium | 2005 |
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Topics: Actinium; Alpha Particles; Apoptosis; Beta Particles; Bismuth; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Radiation; Energy Transfer; Enzyme-Linked Immunosorbent Assay; Humans; Ligands; Lutetium; Mitosis; Models, Statistical; Neoplasms; Octreotide; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin | 2005 |
[Peptide receptor radionuclide therapy of neuroendocrine tumors].
Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Yttrium Radioisotopes | 2009 |
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrinoma; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Radioisotopes; Receptors, Peptide; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Personnel exposure in labelling and administration of (177)Lu-DOTA-D-Phe1-Tyr3-octreotide.
Topics: Beta Particles; Chemistry; Humans; Isotope Labeling; Lutetium; Occupational Exposure; Octreotide; Physicians; Radioisotopes; Skin; Thermoluminescent Dosimetry | 2011 |
The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Topics: Adult; Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Whole-Body Counting | 2013 |
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Topics: Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin | 2013 |
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?
Topics: Blood Cells; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiation Dosage; Radiopharmaceuticals; Receptors, Somatostatin; Spleen | 2013 |
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome | 2016 |
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
Topics: Adult; Female; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals | 2020 |
Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
Topics: Aged; Antineoplastic Agents; Chromogranin A; Female; Humans; Lutetium; Male; Middle Aged; Monte Carlo Method; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome | 2020 |